Nicholas Ashby Clanton

Nicholas Ashby Clanton

Auto-generated profile, based on publicly available information

Nicholas Ashby Clanton

The Max and Minnie Tomerlin Voelcker Laboratory for Organic Chemistry, Department of Chemistry, The University of Texas at San Antonio, San Antonio, Texas 78249, United States

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2017 in Nuclear Medicine and Biology
Verified
Journal Article
Closed access
SQStacy Lee Queern
Stacy Lee Queern
TATolulope Aramide Aweda
Tolulope Aramide Aweda
AMAdriana Vidal Fernandes Massicano
Adriana Vidal Fernandes Massicano
NCNicholas Ashby Clanton
Nicholas Ashby Clanton
RSRetta El Sayed
Retta El Sayed
SLSuzane Lapi
Suzane Lapi

25 February 2021 in Organic Letters
Verified
Journal Article
Closed access
NCNicholas A. Clanton
Nicholas A. Clanton
TSTaylor E. Spiller
Taylor E. Spiller
EOEliezer Ortiz
Eliezer Ortiz
ZGZhinong Gao
Zhinong Gao
JRJuan Manuel Rodriguez-Poirier
Juan Manuel Rodriguez-Poirier
DFDoug E. Frantz
Doug E. Frantz

5 August 2022 in ACS Catalysis
Verified
Journal Article
Closed access
MCMelissa Cadena
Melissa Cadena
RVRoberto Silva Villatoro
Roberto Silva Villatoro
JGJyoti Shah Gupta
Jyoti Shah Gupta
CPCody Phillips
Cody Phillips
JAJonathan B. Allen
Jonathan B. Allen
DFDoug E. Frantz
Doug E. Frantz

2 January 2023 in Organic Letters
Verified
Journal Article
Open access
NCNicholas A. Clanton
Nicholas A. Clanton
NWNicolas A. Wilson
Nicolas A. Wilson
EOEliezer Ortiz
Eliezer Ortiz
SBShawn T. Blumberg
Shawn T. Blumberg
DFDoug E. Frantz
Doug E. Frantz
The site-selective functionalization of unactivated allylic C-H bonds via direct deprotonation using KTMP is described. The conversion of amorphadiene to artemisinic alcohol via a simple, highly regioselective deprotonation over 4 other possible allylic sites is shown with further extrapolation to the first large-scale telescoped chemical synthesis of artemisinic acid from amorphadiene. Finally, application of the method for the successful site-selective functionalization of unactivated allylic C-H bonds in other terpene-based natural products is also highlighted.

20 November 2020 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
NCNicholas A. Clanton
Nicholas A. Clanton
SHShayne D. Hastings
Shayne D. Hastings
GFGriffin B. Foultz
Griffin B. Foultz
JCJulie A. Contreras
Julie A. Contreras
SYSamantha Yee
Samantha Yee
DFDoug E. Frantz
Doug E. Frantz

25 July 2023 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
UPUday Pratap
Uday Pratap
MTMichael Tidwell
Michael Tidwell
HBHenriette U. Balinda
Henriette U. Balinda
NCNicholas A. Clanton
Nicholas A. Clanton
XYXue Yang
Xue Yang
RVRatna Vadlamudi
Ratna Vadlamudi
Glioblastoma (GBM) is the most prevalent and aggressive type of adult brain tumors with low 5-year overall survival rates. Epidemiologic data suggest that estrogen may decrease brain tumor growth, and estrogen receptor beta (ERβ) has been demonstrated to exert antitumor functions in GBM. The lack of potent, selective, and brain permeable ERβ agonist to promote its antitumor action is limiting the therapeutic promise of ERβ. In this study, we discovered that Indanone and tetralone-keto or hydroxyl oximes are a new class of ERβ agonists. Because of its high activity in ERβ reporter assays, specific binding to ERβ in polar screen assays, and potent growth inhibitory activity in GBM cells, CIDD-0149897 was discovered as a possible hit by screening a library of compounds. CIDD-0149897 is more selective for ERβ than ERα (40-fold). Treatment with CIDD-0149897 markedly reduced GBM cell viability with an IC50 of ∼7 to 15 μmol/L, while having little to no effect on ERβ-KO cells and normal human astrocytes. Further, CIDD-0149897 treatment enhanced expression of known ERβ target genes and promoted apoptosis in established and patient-derived GSC models. Pharmacokinetic studies confirmed that CIDD-0149897 has systemic exposure, and good bioavailability in the brain. Mice tolerated daily intraperitoneal treatment of CIDD-0149897 (50 mg/kg) with a 7-day repeat dosage with no toxicity. In addition, CIDD-0149897 treatment significantly decreased tumor growth in U251 xenograft model and extended the survival of orthotopic GBM tumor-bearing mice. Collectively, these findings pointed to CIDD-0149897 as a new class of ERβ agonist, offering patients with GBM a potential means of improving survival.